Trials / Completed
CompletedNCT03925727
Tavilermide Ophthalmic Solution for the Treatment of Dry Eye
Multi-Center, Randomized,Double-Masked, Vehicle-Controlled Study to Assess the Safety and Efficacy Study of Tavilermide Ophthalmic Solutions for the Treatment of Dry Eye
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 623 (actual)
- Sponsor
- Mimetogen Pharmaceuticals USA, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 99 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the safety and efficacy of 5% tavilermide and 1% tavilermide ophthalmic solutions compared with placebo ophthalmic solution in treating the signs and symptoms of dry eye.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tavilermide ophthalmic solution | BID topical dosing |
| OTHER | Placebo | BID topical dosing |
Timeline
- Start date
- 2019-03-28
- Primary completion
- 2020-06-11
- Completion
- 2020-06-11
- First posted
- 2019-04-24
- Last updated
- 2023-04-05
- Results posted
- 2023-03-09
Locations
22 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03925727. Inclusion in this directory is not an endorsement.